Indian markets see renewed investor interest in pharma, speciality chemicals, and exchange-traded services, with recent earnings showing mixed signals. Pharma valuations are attractive, with Sun Pharma and MNCs like GSK and Pfizer showing promise. Speciality chemicals require patience, while BSE’s performance is linked to market sentiment and NSE’s upcoming listing.
Radhika Gupta reveals India’s next 3 wealth creation themes & why SIFs are the investment product of the decade
Radhika Gupta, Edelweiss Mutual Fund CEO, champions Specialised Investment Funds (SIFs) as a new product category offering lower market dependence and higher alpha. She highlighted